Yves Fradet

Q: What Schools Are Affiliated With Yves Fradet

Yves Fradet is affiliated with the following schools: Université de Montréal, MD Anderson Cancer Center, University of Medicine, Taunggyi, University of British Columbia, University of Oklahoma Health Sciences Center, University of Michigan, University of Hamburg, University of Ferrara, Université Laval

Yves Fradet's AcademicInfluence.com Rankings

Yves Fradet

Philosophy

#8120

World Rank

#11443

Historical Rank

Logic

#5153

World Rank

#6528

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Yves Fradet's Degrees

Doctorate Medicine University of Medicine, Taunggyi
PhD Medical Science University of Medicine, Taunggyi

Why Is Yves Fradet Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Yves Fradet's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma (2017) (2186)
PCA3: a molecular urine assay for predicting prostate biopsy outcome. (2008) (461)
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. (2007) (444)
Genomic hallmarks of localized, non-indolent prostate cancer (2017) (427)
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. (2005) (421)
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. (2013) (372)
Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA (2011) (364)
PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata (2007) (337)
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. (2007) (300)
Widespread and Functional RNA Circularization in Localized Prostate Cancer (2019) (280)
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. (2007) (277)
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. (2010) (274)
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. (1984) (273)
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (2014) (254)
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes (2014) (246)
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up (2019) (244)
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. (1998) (240)
Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. (1996) (234)
Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. (2003) (194)
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. (2020) (191)
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. (2009) (187)
uPM3, a new molecular urine test for the detection of prostate cancer. (2004) (187)
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. (2009) (182)
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. (2010) (176)
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. (2012) (174)
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. (2005) (172)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. (2021) (164)
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. (1996) (164)
Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. (1996) (162)
Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. (2013) (159)
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort (2011) (158)
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. (1996) (158)
Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience (2011) (157)
Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus (2014) (156)
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. (2010) (153)
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. (2009) (147)
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy (2010) (147)
p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer (2000) (146)
Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. (2003) (146)
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. (2015) (144)
The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. (1998) (142)
Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. (1999) (139)
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. (2017) (138)
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. (2011) (133)
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. (2013) (133)
The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder (2010) (125)
Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. (1997) (123)
Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31 (1999) (119)
879: PD-L1 (B7-H1) Expression by Urothelial Carcinoma of the Bladder and BCG-Induced Granulomata: Associations with Localized Stage Progression (2007) (119)
Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. (2014) (117)
Evaluation of fluorodeoxyglucose positron‐emission tomography with computed tomography for staging of urothelial carcinoma (2010) (114)
Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. (1993) (114)
Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. (2009) (113)
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. (1993) (112)
Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma (1999) (110)
Insomnia in men treated with radical prostatectomy for prostate cancer (2005) (106)
Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist (1994) (102)
Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. (1999) (100)
Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. (2014) (97)
ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma (2005) (96)
Dietary fat and advanced prostate cancer. (1998) (95)
Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. (2009) (95)
The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. (2013) (92)
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. (2011) (92)
Dietary fat and prostate cancer survival (1999) (91)
Neoadjuvant hormonal therapy: the Canadian experience. (1997) (91)
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. (2018) (89)
Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. (1997) (83)
Prevalence and Clinical Significance of Her-2/neu, p53 and Rb Expression in Primary Superficial Bladder Cancer (1996) (83)
High frequency of MAGE‐A4 and MAGE‐A9 expression in high‐risk bladder cancer (2009) (81)
Bicalutamide (Casodex®) in the treatment of prostate cancer (2004) (80)
Reproducibility of p53 Immunohistochemistry in Bladder Tumors (2000) (79)
p53 expression in patients with advanced urothelial cancer of the urinary bladder (2010) (74)
Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery. (2005) (74)
Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study (2009) (74)
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. (1999) (73)
Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest (2000) (72)
Dietary energy and nutrients in relation to preclinical prostate cancer. (1997) (71)
Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. (2014) (71)
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. (2012) (69)
Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis? (2002) (68)
Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study) (2005) (66)
Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. (2011) (66)
Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. (2010) (66)
Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. (1984) (65)
Alteration of the PATCHED locus in superficial bladder cancer (2003) (64)
Lymphadenectomy for bladder cancer at the time of radical cystectomy. (2013) (64)
Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. (1999) (63)
Dietary Fat and Prostate Cancer Progression and Survival (1999) (62)
Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization (2007) (61)
Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group. (1990) (60)
Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells (1993) (60)
Downward trend in prostate cancer mortality in Quebec and Canada. (1999) (60)
Toll-like receptors in urothelial cells—targets for cancer immunotherapy (2013) (59)
Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics. (1986) (58)
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. (1996) (58)
Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. (2013) (58)
p53 predictive value for pT1-2 N0 disease at radical cystectomy. (2009) (58)
LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 (2020) (57)
The burden of prostate cancer in Canada. (2013) (57)
Safety and outcome of early catheter removal after radical retropubic prostatectomy. (2004) (56)
Toxicity of ribosome‐inactivating proteins‐containing immunotoxins to a human bladder carcinoma cell line (1996) (56)
Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients. (2003) (56)
Carcinoma of the upper urinary tract (2009) (56)
A Controlled Trial of Castration With and Without Nilutamide in Metastatic Prostatic Carcinoma (1990) (56)
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. (2010) (55)
Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. (1995) (54)
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. (2007) (54)
Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. (2004) (53)
Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. (2008) (53)
Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. (1987) (52)
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. (1998) (52)
Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression (2012) (52)
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. (2016) (51)
Large-Scale Automatic Feature Selection for Biomarker Discovery in High-Dimensional OMICs Data (2019) (51)
Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. (2014) (51)
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. (2011) (50)
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. (2015) (50)
Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. (1993) (49)
Toll-like receptors in normal and malignant human bladders. (2011) (49)
Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen (2009) (49)
P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. (2000) (48)
Critical appraisal of tumor markers in bladder cancer. (1993) (48)
Lifetime occupational physical activity and incidental prostate cancer (Canada) (2000) (47)
Placebo‐associated remissions in a multicentre, randomized, double‐blind trial of interferon γ‐1b for the treatment of metastatic renal cell carcinoma (2000) (47)
Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration (2013) (47)
Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (2016) (46)
FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy (2015) (46)
Tissue factor expression correlates with disease‐specific survival in patients with node‐negative muscle‐invasive bladder cancer (2007) (45)
Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. (1995) (45)
Maintenance bacillus Calmette‐Guérin in high‐risk nonmuscle‐invasive bladder cancer (2008) (44)
SRD5A polymorphisms and biochemical failure after radical prostatectomy. (2011) (44)
Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. (1999) (44)
MAGE‐A9 mRNA and protein expression in bladder cancer (2007) (43)
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. (2010) (43)
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. (2012) (43)
Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients (2019) (43)
Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. (1998) (42)
Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer (2014) (42)
Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. (2013) (41)
Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. (2000) (40)
Total androgen ablation: Canadian experience. (1991) (39)
Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. (2013) (38)
Genome-wide germline correlates of the epigenetic landscape of prostate cancer (2019) (38)
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. (2017) (37)
Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. (2010) (37)
Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. (2020) (37)
Canadian Urological Association guideline: Muscle-invasive bladder cancer. (2019) (36)
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota (2022) (36)
The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. (2012) (36)
Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes (2010) (35)
Precision of DNA flow cytometry in inter-institutional analyses. (1991) (35)
Dual-Kidney Transplants as an Alternative for Very Marginal Donors: Long-Term Follow-Up in 63 Patients (2010) (35)
Prognostic markers in muscle invasive bladder cancer (2002) (35)
Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy (2004) (34)
Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. (2005) (33)
Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors. (1992) (33)
Intravesical Chemotherapy of High-Grade Bladder Cancer with HTI-286, A Synthetic Analogue of the Marine Sponge Product Hemiasterlin (2008) (32)
High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. (2013) (32)
The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. (2016) (32)
Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. (2001) (32)
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy (2010) (32)
The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. (2014) (32)
Cancer-testis antigen expression in bladder cancer. (2005) (32)
Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. (2006) (32)
Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. (2013) (31)
Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis (2011) (31)
Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. (2000) (31)
Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens (2016) (30)
Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling (2012) (30)
Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. (1996) (30)
The assessment of disease aggressivity in stage D2 prostate cancer patients (review). (1990) (30)
Monoclonal antibody against a tumor‐associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas (1990) (30)
Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway (2014) (30)
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience (2012) (29)
Accelerated Induction of Bladder Cancer in Patched Heterozygous Mutant Mice (2004) (29)
Tumorigenic pathways in low‐stage bladder cancer based on p53, MDM2 and p21 phenotypes (2000) (29)
Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer. (1996) (28)
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. (1995) (28)
Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. (2011) (28)
Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy (2012) (28)
IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness (2014) (28)
Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. (1991) (27)
pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. (2011) (27)
Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy (2015) (27)
Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature. (2006) (27)
Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer (2013) (27)
1010 HEXVIX® FLUORESCENCE CYSTOSCOPY IMPROVES DETECTION AND RESECTION OF PAPILLARY BLADDER CANCER AND REDUCES EARLY RECURRENCE: A MULTICENTRE, PROSPECTIVE, RANDOMIZED STUDY (2009) (27)
Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. (2010) (27)
THE ETIOLOGY OF BLADDER CANCER‐ARE THERE ANY NEW CLUES OR PREDICTORS OF BEHAVIOR? (1995) (26)
Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. (2014) (26)
Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database. (2012) (26)
Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. (2003) (25)
Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy (2001) (24)
Omega‐3 fatty acids decrease prostate cancer progression associated with an anti‐tumor immune response in eugonadal and castrated mice (2018) (23)
Low frequency of human papillomavirus infection in initial papillary bladder tumors (1999) (23)
Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. (2000) (23)
Poly(I:C) potentiates Bacillus Calmette–Guérin immunotherapy for bladder cancer (2016) (23)
Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. (2019) (22)
The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer‐specific survival (2018) (22)
Quality indicators in the management of bladder cancer: A modified Delphi study. (2017) (22)
Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. (2011) (21)
Intermediate endpoint biomarkers for chemoprevention (1992) (21)
Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery. (1999) (21)
A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer (2015) (21)
Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. (2019) (21)
Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. (20)
An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study (2014) (20)
Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? (2012) (20)
Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). (2018) (19)
Markers of prognosis in superficial bladder cancer. (1992) (19)
Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). (2017) (18)
Ha-ras codon 12 mutation in papillary tumors of the urinary-bladder - a retrospective study. (1994) (18)
Total androgen blockade vs orchiectomy in stage D2 prostate cancer. (1987) (18)
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? (2012) (18)
Biochemical analysis of a bladder-cancer-associated mucin: structural features and epitope characterization. (1997) (18)
MAUB Is a New Mucin Antigen Associated with Bladder Cancer (*) (1996) (18)
Can biological markers predict recurrence and progression of superficial bladder cancer? (2000) (18)
Total androgen blockade for metastatic cancer of the prostate. (1988) (17)
Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder. (1985) (17)
Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. (2012) (17)
Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial (2018) (17)
EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY (2009) (17)
Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case–control study with multicohort validation (2020) (16)
Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate (2019) (16)
Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery (2011) (16)
Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder. (1997) (16)
The detection of genetic markers of bladder cancer in urine and serum (2008) (16)
Substratification of high-risk localised prostate cancer treated by radical prostatectomy (2008) (16)
Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. (1999) (16)
Enhanced urinary prostaglandin E2 in postobstructive diuresis in humans. (1980) (16)
New diagnostic and prognostic tools in bladder cancer (2002) (15)
Biological markers of prognosis in invasive bladder cancer. (1990) (15)
Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer (2014) (15)
DNA slit-scan flow cytometry of bladder irrigation specimens and the importance of recognizing urothelial cells. (1991) (14)
Use of Markers in Defining Urothelial Premalignant and Malignant Conditions (2000) (14)
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy (1996) (14)
Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. (2017) (14)
Antibody drug carrier for immunotherapy of superficial bladder cancer: ultrastructural studies. (1992) (14)
Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. (2018) (13)
Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression (2020) (13)
The role of neoadjuvant androgen deprivation prior to radical prostatectomy. (1996) (13)
Prostate cancer: 4. Screening. (1998) (13)
Recent advances in the management of superficial bladder tumors. (2002) (12)
Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens (2016) (12)
Screening for bladder cancer: the best opportunity to reduce mortality. (2013) (12)
Molecular and immunologic approaches in the management of bladder cancer. (1991) (12)
Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non–Muscle-Invasive Bladder Cancer: A Gene–Smoking Interaction (2015) (12)
[Salvage radical prostatectomy after radiotherapy failure in localized prostatic cancer]. (2002) (12)
Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) (2019) (12)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer. (2006) (12)
Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis. (2015) (11)
Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer (1997) (11)
Immunological activities of rat lymphocytes. II. Isolation of suppressor cells of the mitogenic response of rat thoracic duct lymphocytes. (1975) (11)
Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial. (2018) (11)
Reply to Juan Morote’s Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659–68 (2010) (10)
HEXAMINOLEVULINATE FLUORESCENCE CYSTOSCOPY IMPROVES DETECTION AND RESECTION OF PAPILLARY BLADDER CANCER LESIONS AND REDUCES EARLY RECURRENCES (2009) (10)
Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. (2017) (10)
Regulation of in vitro lymphocyte responses. I. Adjuvant effect of lipopolysaccharide (LPS) on low-zone unresponsiveness to concanavalin A. (1976) (10)
264: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Carcinoma in Situ of the Urinary Bladder (2004) (10)
A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. (2020) (10)
Growth-regulated surface glycoproteins of human bladder cancer. (1990) (10)
Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low‐risk prostate cancer receiving 5α‐reductase inhibitors (2018) (9)
Discordance between testosterone measurement methods in castrated prostate cancer patients (2019) (9)
A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer (2019) (9)
Improved cancer specific‐survival in patients with carcinoma invading bladder muscle expressing cyclo‐oxygenase‐2 (2011) (9)
LYMPHOVASCULAR INVASION IS A POWERFUL PREDICTOR OF CLINICAL OUTCOMES IN NODE-NEGATIVE RADICAL CYSTECTOMY PATIENTS: AN INTERNATIONAL EXTERNAL VALIDATION STUDY (2009) (9)
Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. (2012) (9)
Canadian Consensus Conference: The FDA decision on the use of 5ARIs. (2012) (9)
Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth. (2020) (9)
263: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Stage TA/T1 Urothelial Cancer in the Urinary Bladder (2004) (9)
Identification of a superficial bladder tumor-associated glycoform of the carcinoembryonic antigen by monoclonal antibody 19A211. (1996) (9)
Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study (2014) (8)
CHARACTERIZATION OF LYMPHOCYTOTOXIC ANTIBODIES IN RENAL TRANSPLANTATION (1981) (8)
Renal prostaglandins in postobstructive diuresis. Comparative study of unilateral and bilateral obstruction in conscious dogs. (1988) (8)
Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival (2020) (8)
Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study (2017) (8)
FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST (2009) (8)
COMBINATION OF CELL CYCLE REGULATING BIO-MARKERS IMPROVES PROGNOSIS IN PATIENTS WITH ORGAN CONFINED UROTHELIAL CANCER AT RADICAL CYSTECTOMY (2008) (8)
Flow and image cytometry for DNA analysis in bladder washings: improved concordance by using internal reference for flow. (1993) (8)
Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer (2020) (8)
Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? (2019) (8)
Blood group antigen expression in bladder tumors: An immunohistochemical study of superficial bladder lesions (1994) (8)
[Ipsilateral adrenalectomy in the surgical treatment of renal carcinoma]. (1995) (7)
Tn-MUC 1 DC Vaccination of Rhesus Macaques and a Phase I / II Trial in Patients with Non-Metastatic Castrate Resistant Prostate Cancer (2016) (7)
Bladder cancer markers in patient management: the current perspective (2008) (7)
Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). (2013) (7)
Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. (2018) (7)
297 FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST (2009) (7)
Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion (2022) (7)
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. (2022) (7)
Cell surface differentiation antigens of normal urothelium and bladder tumors. (1992) (7)
The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. (2015) (6)
1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361. (2021) (6)
Total Androgen Blockade for Metastatic Cancer of the Prostate (1987) (6)
Strategies of chemoprevention based on antigenic and molecular of early and premalignant lesions of the bladder (1992) (6)
102 THE PCA3 SCORE IS INDEPENDENT OF PROSTATE GLAND VOLUME, AND CAN SYNERGIZE WITH OTHER PATIENT INFORMATION FOR PREDICTING BIOPSY OUTCOME (2007) (6)
Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. (2018) (6)
LBA37_PRPembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial (2017) (6)
972: Disease Outcome of Patients with A PSA ≥20 Treated by Radical Prostatectomy: Analysis of 177 Patients (2006) (6)
Multicenter study of the UPM3 test, a new molecular urine assay to detect prostate cancer (2003) (6)
Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer? (2020) (6)
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045. (2017) (6)
Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder. (1992) (5)
Summary of effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder (by Harry W. Herr, MD, Carl M. Pinsky, MD, Willet F. Whitmore, Jr, MD, Herbert F. Oettgen, MD, and Myron R. Melamed, MD). 1983. (1997) (5)
Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. (2013) (5)
Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise. (2013) (5)
The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. (2020) (5)
Quebec prostate cancer mortality dropped in 1996. (1998) (5)
BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. (2010) (5)
Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system. (2013) (5)
Phenotypic Characterization of Bladder Cancer (1998) (5)
Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA (2021) (5)
Blood management and radical retropubic prostatectomy: Quebec experience. (1999) (5)
Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment (2022) (5)
Kidney graft survival: role of blood transfusions and lymphocytotoxic antibodies. (1982) (5)
Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. (2015) (5)
851PDSubgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc) (2017) (4)
577 Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis (2013) (4)
[International Prostate Symptom Scale. Evaluation of the usefulness of a French version]. (2000) (4)
VALIDATION OF A NOMOGRAM FOR PREDICTING DISEASE RECURRENCE FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER (1999) (4)
Gleason grading controversies: what the chemoprevention trials have taught us. (2013) (4)
Treatment of superficial bladder cancer (1995) (4)
Reproducibility of p 53 Immunohistochemistry in Bladder Tumors 1 (2000) (4)
897 Gender-specific differences in clinicopathologic outcomes following radical cystectomy: An international multi-institutional study of over 8,000 patients (2014) (4)
747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052 (2020) (4)
Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor‐associated macrophage phenotype (2022) (4)
Should Canadians be offered systematic prostate cancer screening? Yes. (2007) (4)
Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review. (2017) (4)
[The PATCHED/Sonic Hedgehog signalling pathway in superficial bladder cancer]. (2003) (4)
24 TAMOXIFEN AS PROPHYLAXIS FOR PREVENTION OF GYNAECOMASTIA AND BREAST PAIN ASSOCIATED WITH BICALUTAMIDE 150 MG MONOTHERAPY IN PATIENTS WITH PROSTATE CANCER (2007) (4)
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro. (2012) (4)
18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. (2021) (3)
Cancer-testis antigen expression in bladder cancer. (2005) (3)
Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. (2013) (3)
La voie de signalisation PATCHED/Sonic Hedgehog dans le cancer superficiel de la vessie (2003) (3)
1558 PT2-3N0M0 PROSTATE CANCER WITH POSITIVE AND NEGATIVE MARGINS: CLINICAL OUTCOME AND TIME TO SALVAGE RADIOTHERAPY (2010) (3)
Diagnosis of Bladder Cancer (2001) (3)
Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity (2020) (3)
Radioimmunodetection of human bladder tumor xenografts in nude mice with radiolabeled monoclonal antibodies. (1992) (3)
Total Androgen Blockade for Metastatic Cancer of Prostate (1987) (3)
Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression (2020) (2)
Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study (2017) (2)
IMPACT OF PELVIC LYMPHADENECTOMY ON DISEASE- FREE SURVIVAL AFTER RADICAL PROSTATECTOMY: A MULTICENTER STUDY (2008) (2)
Role of radical prostatectomy in high-risk prostate cancer. (2002) (2)
Urologic Paraneoplastic Syndromes (2007) (2)
Controversies in the management of localized prostate cancer: consensus development by Canadian urologists. (2002) (2)
713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL (2013) (2)
Abstract 206: Development of a molecular imaging system based on the transcriptional activity of the DD3/PCA3 non-coding RNA for imaging specifically the prostate cancer cells (2015) (2)
MP-08.12 (2006) (2)
2121 URINE MEASUREMENT OF TMPRSS2:ERG FOR THE EARLY DETECTION OF SIGNIFICANT PROSTATE CANCER (2010) (2)
Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients (2012) (2)
Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer. (2012) (2)
Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens (2021) (2)
Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience. (2012) (2)
Influence of the diagnostic modality on the pathological stage of clinically localized prostatic cancer. (1994) (2)
Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. (2018) (2)
Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy (2021) (2)
Corrélations entre la protéase MMP-2, l’activateur MT1-MMP et l’inhibiteur TIMP-2 dans le cancer de la prostate (2004) (2)
Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]. (2015) (2)
919: Expression of Cyclooxygenase-2 is Associated with Stage, Grade and Recurrence-Free Survival in Superficial Bladder Cancer (2005) (2)
786 Impact of extent of positive margins on different outcome parameters in 1712 treatment-naïve patients after pT2-4 N0 radical prostatectomy (2012) (2)
Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical Prostatectomy (2019) (2)
Adjuvant versus Salvage Radiotherapy in Patients with Positive Surgical Margins at Radical Prostatectomy : That is the Question (2013) (1)
Influence of HLA-A and HLA-B cross-reactive antigen matching on kidney graft survival. (1981) (1)
IMPROVED CANCER SPECIFIC-SURVIVAL IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER EXPRESSING CYCLO-OXYGENASE-2 (2009) (1)
EVALUATION OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY ASSOCIATED WITH COMPUTED TOMOGRAPHY (18F-FDG-PET/CT)IMAGING FOR STAGING OF BLADDER TRANSITIONAL CELL CARCINOMA (2009) (1)
Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy (2013) (1)
PREDICTIVE VALUE OF THE COMBINATION OF IMMUNOHISTOCHEMICAL MARKERS IN PATIENTS WITH PT1 DISEASE AT RADICAL CYSTECTOMY (2009) (1)
GCC expression in lymph nodes (LNs) as a significant determinant of recurrence in stage II colon cancer (CC) patients (pts). (2011) (1)
Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer (2021) (1)
97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (2013) (1)
POD-07.01: Hexaminolevulinate New Data: Results from the Recurrence Study (2009) (1)
1668: Insulin-Like Growth Factor Binding Protein 2 is an Independant Predictor of Prostate Cancer Survival (2004) (1)
Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC). (2021) (1)
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. (2022) (1)
A Festschrift in Honor of Edward M. Messing, MD, FACS (2018) (1)
CONTEMPORARY OUTCOMES OF RADICAL CYSTECTOMY IN 2287 PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A CANADIAN MULTI-INSTITUTIONAL EXPERIENCE (2009) (1)
Apport de la fluxcytométrie à paramètres multiples à la détection et à l'évaluation des tumeurs vésicales humaines (1985) (1)
50: Bacteriologic Profile of Studer Orthotopic Neobladders and the Risk of Urinary Tract Infection (2004) (1)
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways. (2022) (1)
[The use of multiparameter flow cytometry in the detection and evaluation of human bladder tumors]. (1985) (1)
247 PT3 SUBSTAGING IS A PROGNOSTIC INDICATOR IN LYMPH NODE NEGATIVE UROTHELIAL CARCINOMA OF THE BLADDER (2011) (1)
Tissue-arrays of invasive bladder cancer: Validation of the technique and prognostic value of cyclin E, P53, P21 and P27 by immunohistochemical analysis (2003) (1)
Prostatitis and Urethritis (1999) (1)
33 VALIDATION OF THE AJCC TNM SUBSTAGING OF PT2 BLADDER CANCER: DEEP MUSCLE INVASION IS ASSOCIATED WITH SIGNIFICANTLY WORSE OUTCOME (2010) (1)
UP-02.229 Anti-Inflammatory Effects of Fish Oil (Omega-3 Fatty Acids) on Normal Human Prostate Epithelium (2011) (1)
URINE ASSAYS FOR PCA3 AND TMPRSS2:ERG GENE FUSION TO PREDICT THE DIAGNOSIS OF PROSTATE CANCER (2009) (1)
Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression (2020) (1)
Abstract 2815: Urine TMPRSS2:ERG for prostate cancer risk stratification in men with elevated serum PSA (2011) (1)
Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC). (2021) (1)
Selection of monoclonal antibodies for the development of a simple urinary test for bladder tumor detection (1994) (1)
Reply from authors re: Martin Spahn, Steven Joniau. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur Urol 2013;64:26-8: adjuvant versus salvage radiotherapy in patients with positive surgical margins at radical prostatectomy: that (2013) (1)
Rebuttal: Should Canadians be offered systematic prostate cancer screening? YES. (2007) (1)
767 Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: A multicenter analysis of 742 patients (2012) (0)
Androgens in Prostate Cancer-Reductase Gene Polymorphisms on Circulating α Importance of 5 (2014) (0)
Subject Index Vol. 38, 2000 (2000) (0)
2320 INITIAL AND REPEAT PROSTATE BIOPSY: COMPARATIVE PERFORMANCE ANALYSIS OF PSA, %FPSA, PROSTATE VOLUME AND URINARY PCA3 INCLUDING DEVELOPMENT OF NOVEL PCA3 CUT-OFF THRESHOLDS (2011) (0)
MP79-11 IMPACT OF KI67 LABELING INDEX ON PROGRESSION AND DEATH OF PROSTATE CANCER POST-PROSTATECTOMY: COMPARISON OF VISUAL AND AUTOMATED SCORING (2014) (0)
MP1-03 VALIDATED URINE-BASED MULTIGENE SIGNATURE FOR DETECTION OF AGGRESSIVE PROSTATE CANCER (2015) (0)
Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts). (2013) (0)
PD13-10 THE PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS RISK FACTORS AMONG PROSTATE CANCER PATIENTS TREATED WITH AND WITHOUT ANDROGEN DEPRIVATION (2020) (0)
Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate (2019) (0)
PROGNOSTIC VALUE OF LYMPH NODE DENSITY IN A MULTI-CENTER, INTERNATIONAL COHORT OF PATIENTS WITH NODE POSITIVE UROTHELIAL CARCINOMA OF THE BLADDER (2009) (0)
276 Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy (2013) (0)
2122 COPY NUMBER VARIATION OF SEX-STEROID METABOLIZING GENES AS BIOMARKERS OF PROSTATE CANCER RECURRENCE AFTER PROSTATECTOMY: LOOKING AT THE END OF THE ANDROGENIC SIGNAL (2010) (0)
IMPROVED PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED BLADDER CANCER USING A PANEL OF FOUR CELL CYCLE REGULATORS (2009) (0)
Targeting the androgen receptor axis to improve response to bladder cancer immunotherapy (2022) (0)
UP-02.084 Active Inflammatory State and Reactivity of Normal Prostate Epithelium and Aggressive Prostate Cancer (2011) (0)
1709: The PCA3 Score is Independent of Prostate Gland Volume, and Can Synergize with other Patient Information for Predicting Biopsy Outcome (2007) (0)
542 IMPROVED PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED BLADDER CANCER USING A PANEL OF FOUR CELL CYCLE REGULATORS (2009) (0)
POD-04.08: Treatment outcome of immediate versus delayed hormone therapy in patients with lymph node metastases following radical prostatectomy (2007) (0)
Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361. (2022) (0)
Development of a Molecular Imaging System Based on the Transcriptional Activity of the DD3/PCA3 Non-coding RNA for Imaging Specifically the Prostate Cancer Cells (2014) (0)
1709 ACHIEVING PT0N0 AT RADICAL CYSTECTOMY: OUTCOMES OF 135 PT0N0 BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY: THE CANADIAN BLADDER CANCER NETWORK EXPERIENCE (2009) (0)
322 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH PT4 UROTHELIAL CARCINOMA AT RADICAL CYSTECTOMY: A RETROSPECTIVE INTERNATIONAL STUDY OF 583 PATIENTS (2010) (0)
La voie de signalisationTCHED/Sonic Hedgehog le cancer superficiel vessie (2003) (0)
241 DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS (2013) (0)
Abstract LBA030: DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model (2021) (0)
Pca3 mrna in benign and malignant prostate tissues (2000) (0)
Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder (2013) (0)
Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052. (2022) (0)
Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective. (2022) (0)
Raman microscopy for the identification of an aggressive variant of prostate cancer, intraductal carcinoma of the prostate (2019) (0)
MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY (2019) (0)
1628: Dual-Kidney Transplants as an Alternative for Marginal Donors (2005) (0)
Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study (2023) (0)
1906 POSITIVE SURGICAL MARGINS CONTRIBUTE TO DELAYED FAILURES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2012) (0)
Screening for prostate cancer: a urological perspective. (1994) (0)
Abstract A28: Mutational landscape of TP53 in localized prostate cancer (2017) (0)
Incidence, histology and follow-up of unsuspected prostatic cancer in patients undergoing radical cystoprostatectomy for bladder cancer (2003) (0)
1892 PT2 SUBSTAGING IN UROTHELIAL CARCINOMA OF THE BLADDER: DEEP MUSCLE INVASION IS ASSOCIATED WITH WORSE OUTCOME (2011) (0)
[Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer]. (1996) (0)
89PD Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis (2019) (0)
Identification of two genes differentially expressed upon different spatial configuration of the MGH-U3 human bladder cancer cells. (2002) (0)
MP57-20 VARIANT HISTOLOGY DOES NOT PREDICT SURVIVAL OUTCOMES AFTER RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA: RESULTS FROM THE CANADIAN UPPER TRACT COLLABORATION (2015) (0)
1297 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR PREOPERATIVE STAGING AND POSTOPERATIVE FOLLOW-UP OF UROTHELIAL CARCINOMA (2013) (0)
313 ADJUVANT CHEMOTHERAPY FOR UROTHELIAL CARCINOMA OF THE URINARY BLADDER (2010) (0)
Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture (2016) (0)
C ontemporary Management of Bladder Cancer (2007) (0)
The Significance of Immune Cytological Diagnostics for Bladder Carcinoma (1991) (0)
Northeastern Section of the AUA 72nd Annual Meeting Abstracts (2020) (0)
Abstract 3448: Overexpression of the steroid inactivating UGT2B28 enzyme is associated with high circulating androgens, tumor aggressiveness and adverse prostate cancer outcome (2015) (0)
322 Development and validation of a post-DRE urine-based multigene signature for detection of aggressive prostate cancer prior to biopsy (2015) (0)
MULTI-INSTITUTIONAL EVALUATION OF THE PREDICTIVE VALUE OF P53 IMMUNOHISTOCHEMICAL STAINING IN PATIENTS WITH PT1-2 N0 DISEASE AT RADICAL CYSTECTOMY (2008) (0)
263 Development of novel PCA3 cut-offs for initial and repeat biopsy using different statistical approaches within a US-European multi institutional cohort (2012) (0)
1028 IS PROSTATE-SPARING DURING RADICAL CYSTECTOMY ADVISABLE? (2010) (0)
7115 Prognostic value of cyclooxygenase-1 and cyclooxygenase-2 expressions in human renal cell carcinoma (2009) (0)
1890 HISTOPATHOLOGICAL EVALUATION OF BLADDER CANCER IS RELIABLE EVEN ON AN INTERCONTINENTAL SCALE: COMPARISON OF LOCAL AND CENTRALLY REVIEWED HISTOPATHOLOGY FOR A MULTICENTER INTERCONTINENTAL TRIAL (2011) (0)
The treatment of prostate cancer: how is failure defined and how can it be minimized? (1997) (0)
Patterns of Systemic Chemotherapy Use in Metastatic Castration Resistant Prostate Cancer Patients: A Population-based Study (2014) (0)
Supplementary data: Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review (2017) (0)
Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer. (2016) (0)
PD27-01 EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2014) (0)
Urological Oncology : Bladder , Penis and Urethral Cancer , and Basic Principles of Oncology Re : Factors Influencing the Length of Stay after Radical Cystectomy : Implications for Cancer Care and Perioperative Management (2016) (0)
1210 BIOPSY-SPECIFIC PCA3- BASED PROSTATE BIOPSY NOMOGRAMS ARE HIGHLY ACCURATE (2012) (0)
Recommendations for long-term monitoring in primary care ( all recommendations Level (2016) (0)
Tomlins Men with Elevated Serum PSA Fusion Transcript Stratifies Prostate Cancer Risk in TMPRSS 2 : ERG Urine (2011) (0)
Abstract 2966: The mutational landscape of localized gleason 6 and 7 prostate cancer (2015) (0)
844 PHASE II STUDY OF TREATMENT WITH 5-ALPHA REDUCTASE INHIBITORS (5ARIS) IN LOW RISK PROSTATE CANCER (2009) (0)
Steroidogenesis and Modifies the Risk of Prostate Cancer Progression (2016) (0)
255: Risk Factors for Bladder Cancer Recurrence Following Urothelial Carcinoma of the Upper Urinary Tract (2004) (0)
MP06-13 TARGETING THE ANDROGEN RECEPTOR AXIS TO IMPROVE RESPONSE TO BLADDER CANCER IMMUNOTHERAPY (2022) (0)
Contents Vol. 38, 2000 (2000) (0)
Pca3 mrna in good and mastile prostate weave (2000) (0)
POD-07.10: Outcome Analysis of Bladder Cancer Patients Treated with Radical Cystectomy in a Universal Health Care System: A Multicenter Canadian Series of 2,287 Patients (2009) (0)
Vol. 35, 1999 (1999) (0)
MP-08.01: Salvage therapy with bicalutamide 150 mg in patients with PSA failure under LHRH therapy or surgical castration for advanced prostate cancer (2007) (0)
1835 RISK-STRATIFIED SURVEILLANCE GUIDELINES FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER: THE CANADIAN BLADDER CANCER NETWORK EXPERIENCE (2010) (0)
641 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON score ≥ 7) AT BIOPSY (2011) (0)
744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC) (2020) (0)
APTIMA® PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer (2005) (0)
POD-07.09: Incidental Adenocarcinoma of the Prostate Discovered at the Time of Radical Cystectomy: Analysis of the Canadian Bladder Cancer Network Database (2009) (0)
Poster Session 54PROGNOSTIC BIOMARKERSMonday, 19 April, 14.00-15.30, Paris Room871 URINE MEASUREMENT OF TMPRSS2: ERG FOR THE EARLY DETECTION OF SIGNIFICANT PROSTATE CANCER (2010) (0)
Réfutation: Devrait-on offrir aux Canadiens le dépistage systématique du cancer de la prostate?: OUI (2007) (0)
1400 CLINICAL NODAL STAGING SCORES FOR BLADDER CANCER A NEW PREOPERATIVELY NODAL ASSESSMENT TOOL (2012) (0)
PD-11.02: Cycle-dependent response to maintenance BCG in high-risk superficial bladder cancer (2006) (0)
Prognostic Significance of Tonsil Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence (2016) (0)
Abstract P001: The gut microbiome-prostate tumor crosstalk is modulated by dietary polyunsaturated fatty acids (2022) (0)
Subject Index Vol. 35, 1999 (1999) (0)
MP61-13 DEVELOPMENT OF A MOLECULAR IMAGING SYSTEM BASED ON THE TRANSCRIPTIONAL ACTIVITY OF THE DD3/PCA3 NON-CODING RNA FOR IMAGING SPECIFICALLY THE PROSTATE CANCER CELLS (2015) (0)
Diagnosis and monitoring of bladder tumours using immunoCyt/uCyt+ in routine clinical practiced monitoring (2003) (0)
Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence. (2016) (0)
Precise Morphologic Documentation with Large-format (2013) (0)
1032 VALIDATION OF RESIDUAL PATHOLOGIC STAGE AT RADICAL CYSTECTOMY AS A PROGNOSTIC FACTOR IN PATIENTS WITH CT2N0 BLADDER CANCER (2010) (0)
515 EXTENT OF LYMPHADENECTOMY AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: A MULTICENTER STUDY (2009) (0)
POD-4.11: Extent of Lymphadenectomy and Biochemical Recurrence After Radical Prostatectomy: A Multicenter Study (2008) (0)
Abstract LB-65: A gene expression predictor of pathological node stage of urothelial bladder cancer (2010) (0)
56: Utility of Routine Urine Cytology in the Followup of Patients with Studer Orthotopic Neobladders (2004) (0)
La voie de signalisation Hedgehog le cancer superficiel vessie (2003) (0)
911 Biopsy-specific PCA3-based prostate biopsy nomograms are highly accurate (2012) (0)
RADIOTHERAPY OF THE PRIMARY TUMOUR FOR METASTATIC PROSTATE CANCER (2016) (0)
Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study. (2021) (0)
Analysis of sex-based differences in response to bacillus Calmette- Guérin for non-muscle-invasive bladder cancer (2022) (0)
Increased prostate cancer glucose metabolism detected by FDG-PET/CT in localised Gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration (2018) (0)
Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer. (2022) (0)
Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials. (2022) (0)
The use of antibiotic prophylaxis in patients undergoing radical cystectomy for bladder cancer (2017) (0)
Serial FDG-PET imaging of metastatic prostate cancers reveals intrapatient intermetastases polyclonality through same patient heterogeneous responses to systemic therapy. (2017) (0)
ELECTROMOTTVE DRUG ADMINISTRATION OF LIDOCAINE AS AN ALTERNATI \ TE A } IESTHESIA FOR TRANSURETHRAL SURGERY (2011) (0)
1293 A META-ANALYSIS OF BLUE LIGHT CYSTOSCOPY WITH HEXAMINOLEVULINATE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (2013) (0)
538: Protoype Aptima® PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer (2006) (0)
Abstract 118: A comprehensive profile of the genomic architecture of curable prostate cancer (2016) (0)
1465: Effects of Systematic Use of Ureteral Stent in Renal Transplantation (2006) (0)
The Combination of Multiple Cell Cycle Regulators Improves Prognosis in Patients with Pathologic Organ-Confined Bladder Cancer: A Multicenter External Validation Study (2010) (0)
1982 NODAL YIELD IS NOT INDEPENDENTLY ASSOCIATED WITH SURVIVAL IN PATIENTS WITHOUT NODAL METASTASIS AT RADICAL CYSTECTOMY (2011) (0)
TREATMENT OUTCOME OF IMMEDIATE VERSUS DELAYED HORMONE THERAPY IN PATIENTS WITH LYMPH NODE METASTASES FOLLOWING RADICAL PROSTATECTOMY (2008) (0)
Méthodes, kits et compositions pour réaliser une évaluation clinique d'un cancer prostatique (2013) (0)
271 - Analyse de la qualité de vie des hommes à risque de cancer de la prostate (2022) (0)
Marqueurs moléculaires du cancer infiltrant de la vessie (2002) (0)
Anticorps monoclonaux contre les cancers de la vessie et de l'uretre chez les humains et methode de preparation (1984) (0)
Composition immunologique de detection du cancer de la vessie, et son mode d'utilisation (1997) (0)
Nouvelles protéines de liaison à un antigène (2011) (0)
Devrait-on offrir aux Canadiens le dépistage systématique du cancer de la prostate?: NON (2007) (0)
Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial (2018) (0)
1410 RADICAL CYSTECTOMY FOR CLINICALLY MUSCLE INVASIVE BLADDER CANCER: DOES PRIOR NON-INVASIVE DISEASE AFFECT CLINICAL OUTCOMES? (2012) (0)
Superficial bladder cancer: Diagnosis and staging. Cover story (1996) (0)
Chapter 20 – Transurethral Surgery of Bladder Tumors (2005) (0)
Monoclonal antibodies against human kidney cancer antigens and procedures. (1984) (0)
Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA) (2023) (0)
POD-4.10: Phase II Study of Treatment with 5-Alpha Reductase Inhibitors (5ARIs) in Low-Risk Prostate Cancer (2008) (0)
Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361. (2021) (0)
Gene gpx2, cible specifique et sensible pour le diagnostic, le pronostic et/ou la theranose concernant le cancer du poumon (2005) (0)
35 CONCOMITANT CARCINOMA IN SITU IS NOT ASSOCIATED WITH CLINICAL OUTCOMES AFTER RADICAL CYSTECTOMY (2010) (0)
1401 IS THE NODAL YIELD ASSOCIATED WITH OUTCOMES IN BLADDER CANCER PATIENTS WITHOUT NODAL METASTASIS AT RADICAL CYSTECTOMY (2012) (0)
Genetic and molecular markers in the prognosis of bladder cancer. (1998) (0)
Contemporary Management of Bladder Cancer: Identifying patients who are at risk. (1991) (0)
[Modulation of lymphocyte proliferation by serum factors and lipopolysaccharide]. (1977) (0)
UP-03.117 Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: Assessment of Adequate Renal Function and Impact on Outcome (2011) (0)
POD-07.07 Long-Term Cancer Outcomes After Radical Prostatectomy and Selective Salvage Radiotherapy in 1670 Pt2-3N0M0 Patients by Margins Status: Quantification of Overtreatment with Adjuvant Radiotherapy for all Positive Margins (2011) (0)
1826 OUTCOMES FOR PATIENTS WITH PT3-4 OR PN+ BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: CANADIAN BLADDER CANCER NETWORK (2010) (0)
Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. (2010) (0)
Abstract 4764: Development of a multigenic bioluminescence imaging system to detect prostate cancer cells and assess their response to therapy (2016) (0)
1825 CLINICAL OUTCOME IN PATIENTS WITH PT4 UROTHELIAL CARCINOMA AT RADICAL CYSTECTOMY (2010) (0)
Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP). (2016) (0)
Relations entre habitudes de vie, microbiote intestinal et risque de cancer de la prostate (2022) (0)
2199 GLUT-1, GLUT-12 AND HK2 PROTEIN EXPRESSION IN PROSTATIC ADENOCARNINOMA: CLINICAL CORRELATION WITH INTRAPROSTATIC 18F-FDG-POSITRON EMISSION TOMOGRAPHY (FDG-PET) UPTAKE (2013) (0)
Bladder cancer screening in an occupationally exposed cohort: Implications for bladder cancer management (1997) (0)
Sharing the responsibility of prostate cancer risk reduction (2013) (0)
2288 PROGNOSTIC IMPACT OF INHERITED GENETIC VARIATIONS IN SRD5A AND ANDROGEN INACTIVATING UGT2B GENES IN PROSTATE CANCER AFTER PROSTATECTOMY (2011) (0)
987 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON SCORE ≥ 7) AT BIOPSY (2011) (0)
Association between baseline bone mineral density testing and the risk of fractures in men initiating androgen deprivation therapy: Population-based study (2022) (0)
641 MANAGEMENT OF THE INTRAVESICAL URETER AND BLADDER CUFF DURING RADICAL NEPHROURETERECTOMY: OUTCOMES FROM THE CANADIAN UPPER TRACT COLLABORATION (2012) (0)
Antigenic masking: modification of a tumor cell surface antigen (OM5) by progressive sialylation (1985) (0)
Observance aux lignes directrices pour le traitement par approche multimodale chez les patients atteints de carcinome non-urothélial de la vessie pt2-3 non-métastatique : tendances à travers le temps et analyses de survie (2019) (0)
The management of high-risk prostate cancer in 2008 (2008) (0)
1762 REGIONAL DIFFERENCES IN PRACTICE PATTERNS AND OUTCOMES AFTER RADICAL CYSTECTOMY (2012) (0)
UP-02.184 Urinary PCA3 and Cancer Progression Under Active Surveillance of Prostate Cancer (2011) (0)
Sex steroid modulation of macrophages within the prostate tumor microenvironment. (2022) (0)
227: Prognostic Significance of Tonsl Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence (2016) (0)
Assembling a network to promote translational bladder cancer research in Canada (2020) (0)
Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate. (2021) (0)
Invasive bladder cancer: time is of the essence. (2013) (0)
603 Clinical nodal staging scores for bladder cancer: A proposal for preoperative risk-assessment (2012) (0)
[Immunologic activities of lymphocytes in rats. IV. Chronologic functional variation of lymphocytes of the thoracic duct]. (1977) (0)
612: Tissue Factor Expression as a Prognosis Factor in Patients with Muscle-Invasive Bladder Cancer Treated by Radical Cystectomy (2005) (0)
612: Alterations of the Sonic Hedgehog Pathway in Human Superficial Bladder Cancer: Loss of PTC and GLI Expression (2006) (0)
Acknowledgement to reviewers (1998) (0)
1107: Predictors of Survival for Carcinomas of the Upper Urinary Tract (2006) (0)
[Molecular markers of infiltrating cancer of the bladder]. (2002) (0)
THE USE OF ANTIBIOTIC PROPHYLAXIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER: MP21‐08 (2017) (0)
DECIPHERING THE EFFECTS OF OMEGA‐3 FATTY ACID SUPPLEMENTS ON PROSTATE CANCER: MP70‐17 (2018) (0)
868 TOLL-LIKE RECEPTOR 3 AS A POTENTIAL THERAPEUTIC TARGET IN BLADDER CANCER (2011) (0)
Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361. (2022) (0)
[The treatment of localized cancer of the prostate using radioactive iodine implants]. (1985) (0)
Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis. (2012) (0)
The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation (2020) (0)
Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer. (2016) (0)
671 PREDICTIVE VALUE OF THE COMBINATION OF IMMUNOSTOCHEMICAL MARKERS IN PATIENTS WITH PT1 DISEASE AT RADICAL CYSTECTOMY (2009) (0)
Theraputic Antitumor Effect of Intratumoral Injection of RF-MCD40L in A B Cell Lymphoma Model (2006) (0)
Building a Canadian Translational Bladder Cancer Research Network. (2020) (0)
PD30-03 PSYCHOLOGICAL MORBIDITY ASSOCIATED WITH A NEW DIAGNOSIS OF PROSTATE CANCER: RATES AND PREDICTORS OF DEPRESSIVE SYMPTOMS IN THE RADICAL PC STUDY (2019) (0)
A survey of urological manpower, technology, and resources in Canada. (2004) (0)
621 PT2-3N0M0 PROSTATE CANCER WITH POSITIVE AND NEGATIVE MARGINS: CLINICAL OUTCOME AND TIME TO SALVAGE RADIOTHERAPY (2010) (0)
323 INTERNATIONAL VALIDATION OF THE PROGNOSTIC VALUE OF LYMPHOVASCULAR INVASION IN RADICAL CYSTECTOMY PATIENTS (2010) (0)
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. (2023) (0)
1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study (2022) (0)
Running title : GSTM1, UGT1A1 and smoking status predict recurrence of NMIBC (2015) (0)
Le traitement du cancer localisé de la prostate par implantation d'iode radioactif (1985) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Yves Fradet?

Yves Fradet is affiliated with the following schools: